ORPHA:98843
Classic Hodgkin lymphoma, nodular sclerosis type
Publications
3,778
90.4th percentile
Trials
15
Interventional, condition-specific
Researchers
1,260
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020327
- MONDO:0004665
- UMLS:C0152268
- NCIT:C3518
Additional Mondo synonyms (13)
Hodgkin lymphoma, nodular sclerosis · Hodgkin's disease nodular sclerosis · Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality) · Hodgkin's disease, nodular sclerosis of unspecified site · Hodgkin's nodular sclerosis · NSCHL · NSHD · NSHL · nodular sclerosis Classic Hodgkin lymphoma · nodular sclerosis Hodgkin lymphoma · nodular sclerosis Hodgkin's disease · nodular sclerosis Hodgkin's lymphoma · nodular sclerosis classical Hodgkin lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,778 matched papers (1,918 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
15 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,778
3,778 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,778 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,918 in the last 10 years · medium confidence · 90.4th percentile (publications denominator)
Phrase hits: 3,778 · MeSH hits: 0
Who's working on it?
1,260
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hansmann ML4 papers · 2026
Reference and Consultant Center of Lymph Node and Lymphoma Pathology at Dr. Senckenberg Institute for Pathology, Frankfurt/Main, Hessen, Germany.
Papers in Europe PMC - 02Liu Y4 papers · 2026
Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
Papers in Europe PMC - 03Medeiros LJ4 papers · 2026
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Papers in Europe PMC - 04Nakamura S4 papers · 2023
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Papers in Europe PMC - 05Satou A4 papers · 2023
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Papers in Europe PMC - 06Takahara T4 papers · 2023
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Papers in Europe PMC - 07Wurzel P4 papers · 2026
Department of Molecular Bioinformatics, Johann Wolfgang Goethe-University Frankfurt/Main, Frankfurt/Main, Hessen, Germany.
Papers in Europe PMC - 08Zhang Q4 papers · 2025
Department of Nuclear Medicine, Lu'an People's Hospital of Anhui Province, Lu'an, China.
Papers in Europe PMC - 09Chen Y3 papers · 2025
Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 10Dierickx D3 papers · 2025
Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
15
interventional trials for this specific condition
15 interventional trials matched this specific condition name; none in our sample are currently recruiting. 43 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
15 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94th percentile).
medium confidence · 94th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
15 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: classic Hodgkin lymphoma
43
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07572123·NOT YET RECRUITING·Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Not reviewed·Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06190067·RECRUITING·Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Not reviewed·Conditions: Relapsed Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07097363·RECRUITING·Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Not reviewed·Conditions: B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT06377540·RECRUITING·MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Not reviewed·Conditions: Autologous Stem Cell Transplant · Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07021989·NOT YET RECRUITING·ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Not reviewed·Conditions: Hodgkin Lymphoma, Adult · Refractory Hodgkin Lymphoma · Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06465446·NOT YET RECRUITING·A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
Not reviewed·Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06642792·RECRUITING·A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Not reviewed·Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06170489·RECRUITING·A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Not reviewed·Conditions: Hodgkin Lymphoma·Matched via name phrase
- NCT05955105·RECRUITING·A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Not reviewed·Conditions: Head and Neck Cancer · Cervical Cancer · Endometrial Cancer · Triple Negative Breast Cancer·Matched via name phrase
- NCT05039073·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Not reviewed·Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06916416·NOT YET RECRUITING·Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Not reviewed·Conditions: Classical Hodgkin Lymphoma·Matched via name phrase
- NCT05949931·RECRUITING·Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Not reviewed·Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07275216·RECRUITING·Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Not reviewed·Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT04561206·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Not reviewed·Conditions: Relapsed Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06745076·RECRUITING·Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Not reviewed·Conditions: Advanced Hodgkin Lymphoma · Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 60 · after dedupe 60 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 60 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (60)
- ctis·2024-520138-31-00·Authorised, ongoing·PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2022-501458-13-01·Authorised, ongoing·Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-517756-35-00·Cancelled·A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
skipped — LLM skipped (--skip-llm)
- ctis·2025-524241-27-00·Authorised·A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2026-525263-41-00·Authorised·Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523005-15-00·Authorised, recruiting·A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2025-522523-96-00·Authorised·A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2023-507597-40-00·Authorised·A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522371-29-00·Authorised, ongoing·A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521735-36-00·Authorised, ongoing·A single-arm, multicenter, open-label, Phase I/II trial of Allo-QuadCAR01-T, an allogeneic CAR-T-cell therapy targeting CD19 and CD20, for the treatment of relapsed or refractory B-cell malignancies
skipped — LLM skipped (--skip-llm)
- ctis·2024-510575-38-00·Authorised, ongoing·Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-519498-20-00·Authorised, ongoing·An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
skipped — LLM skipped (--skip-llm)
- ctis·2024-515593-27-00·Authorised, ongoing·A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-519812-15-00·Authorised, ongoing·ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
skipped — LLM skipped (--skip-llm)
- ctis·2024-519318-30-00·Authorised, ongoing·Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
skipped — LLM skipped (--skip-llm)
- ctis·2023-505789-27-00·Authorised, ongoing·A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )
skipped — LLM skipped (--skip-llm)
- ctis·2023-506206-38-00·Authorised, ongoing·A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL).
skipped — LLM skipped (--skip-llm)
- ctis·2024-520123-83-01·Expired·A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519790-19-00·Authorised, ongoing·IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
skipped — LLM skipped (--skip-llm)
- ctis·2024-515624-36-00·Expired·Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.
skipped — LLM skipped (--skip-llm)
- ctis·2024-515457-21-00·Authorised, ongoing·An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
skipped — LLM skipped (--skip-llm)
- ctis·2024-515063-66-00·Authorised, ongoing·Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles (RAFTING-2019)
skipped — LLM skipped (--skip-llm)
- ctis·2023-510556-22-00·Expired·HOVON 136 NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (RDHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation.
skipped — LLM skipped (--skip-llm)
- ctis·2024-515064-31-00·Authorised, ongoing·Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
skipped — LLM skipped (--skip-llm)
- ctis·2024-518022-33-00·Cancelled·HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Classic Hodgkin lymphoma, nodular sclerosis type — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Classic Hodgkin lymphoma, nodular sclerosis type" OR "Hodgkin lymphoma, nodular sclerosis" OR "Hodgkin's disease nodular sclerosis" OR "Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality)" OR "Hodgkin's disease, nodular sclerosis of unspecified site" OR "Hodgkin's disease, nodular sclerosis of the unspecified site" OR "Hodgkin's nodular sclerosis" OR "NSCHL" OR "nodular sclerosis Classic Hodgkin lymphoma" OR "nodular sclerosis Hodgkin lymphoma" OR "nodular sclerosis Hodgkin's disease" OR "nodular sclerosis Hodgkin's lymphoma" OR "nodular sclerosis classical Hodgkin lymphoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Classic Hodgkin lymphoma, nodular sclerosis type" OR "Hodgkin lymphoma, nodular sclerosis" OR "Hodgkin's disease nodular sclerosis" OR "Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality)" OR "Hodgkin's disease, nodular sclerosis of unspecified site" OR "Hodgkin's disease, nodular sclerosis of the unspecified site" OR "Hodgkin's nodular sclerosis" OR "NSCHL" OR "nodular sclerosis Classic Hodgkin lymphoma" OR "nodular sclerosis Hodgkin lymphoma" OR "nodular sclerosis Hodgkin's disease" OR "nodular sclerosis Hodgkin's lymphoma" OR "nodular sclerosis classical Hodgkin lymphoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 15 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"classic Hodgkin lymphoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: NSHD; NSHL
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:34:03.864Z